Shares of Avidity Biosciences surged to a record high Wednesday after the company showed its hand in the cardiovascular space ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss. Please watch the video at Investors.com - How ...

Shares of pharmaceutical giant Amgen (AMGN) are attempting to bounce back after suffering a steep drop of 7.1% yesterday.

On Tuesday, a Cantor analyst wrote that additional data from Amgen’s experimental weight loss injection, MariTide, suggests a ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a ...

Amgen shares dropped over 7% Tuesday after bone density data from an early-stage trial of its weight loss drug, MariTide, ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

An analyst note raising questions about Amgen’s MariTide triggered a stock sell-off Tuesday. Elsewhere, Roche and Novartis ...

In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...

After Sezzle (SEZL) rallied from $200 to over $400, the stock lost 13.87% on Tuesday. The stock drop could continue, depending on how many investors sell to lock in their profits. Sezzle has strong ...

Shares of Amgen (NASDAQ:AMGN) rebounded Wednesday as analysts chewed over bone density loss data from an early-stage trial on its experimental weight loss injection, MariTide. One analyst said the ...

WASHINGTON (Reuters) - U.S. consumer prices increased as expected in October, and progress towards low inflation has slowed ...